GlassScriptPhysician profile
Nidal B Radwan
NPI 1902856875
$4,292.86
in general payments reported to CMS, 2019-2025
30 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $781 · 2021: $697 · 2022: $342 · 2023: $549 · 2024: $655 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,201.97 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $546.99 | 2019-2024 | Xarelto |
| Sunovion Pharmaceuticals INC. | $329.16 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $274.11 | 2021-2024 | Rexulti |
| Novo Nordisk INC | $268.40 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $252.16 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $162.34 | 2019-2020 | |
| Global Blood Therapeutics, INC. | $145.64 | 2020-2022 | |
| Horizon Therapeutics Plc | $138.48 | 2022-2023 | Krystexxa |
| Amgen INC. | $133.09 | 2024-2025 | Krystexxa |
| Angiodynamics, INC. | $118.67 | 2019 | |
| Viiv Healthcare Company | $116.50 | 2025 | Dovato, Apretude |
| Lilly USA, LLC | $106.64 | 2020-2025 | Zepbound, Mounjaro |
| Acell, INC. | $71.97 | 2020 | |
| Sk Life Science, INC. | $61.09 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.42 | 2019 | |
| Smith+Nephew, INC. | $42.32 | 2025 | Collagenase Santyl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.65 | 2019 | |
| Glaxosmithkline, LLC. | $39.79 | 2021-2023 | Trelegy Ellipta |
| Neurelis, INC. | $26.56 | 2025 | Valtoco |
| Amarin Pharma, INC. | $20.70 | 2019 | |
| Shield Therapeutics INC | $19.18 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $18.77 | 2023 | Austedo |
| Abbott Laboratories | $18.05 | 2025 | Freestyle Libre |
| Gilead Sciences, INC. | $17.61 | 2020 | |
| Emmaus Medical, INC. | $17.00 | 2019 | |
| Sun Pharmaceutical Industries INC. | $16.91 | 2021 | |
| Insightec,INC | $15.45 | 2025 | Exablate |
| Lucid Diagnostics INC. | $12.95 | 2022 | |
| Currax Pharmaceuticals LLC | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidal Radwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.